STRONG - Study of AGN1 LOEP for the Treatment of the Contralateral Femur After Fragility Fracture

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

13 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-15

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the procedure and safety profile of the AGN1 Femoral LOEP Kit. This pilot study will be used to evaluate AGN1 Femoral LOEP treatment in a contralateral proximal femur during hip fracture repair.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

NCT04796350

Fragility Fracture Hip Fractures Osteoporosis

RECRUITING NA

Copley II: Long-term Outcome Follow-up Study of Osteoporotic Women Who Underwent a Local Osteo-Enhancement Procedure (LOEP) in the Proximal Femur

NCT06799143

Osteopenic Women Proximal Femur Fracture

COMPLETED

Treatment of Unstable Trochanteric Fractures With the Proximal Femoral Nail - Antirotation (PFNA)-Asia

NCT00873548

Trochanteric Fractures

COMPLETED

3D-printed Bone Models in Addition to CT Imaging for Intra-articular Fracture Repair

NCT04748016

Distal Humerus Fracture Distal Femur Fracture Distal Tibia Fracture +1 more

UNKNOWN NA

Retrograde Femoral Nail-Advanced Outcomes for Fixation of Distal Femur and Femoral Shaft Fractures

NCT05680987

Femoral Fracture

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research will be conducted as a prospective single-center study within Hong Kong. The maximum number of subjects to be treated is twenty (20). This will be a non-randomized and non-blinded study.

Subjects having had a fragility hip fracture on one side will be treated with LOEP in the contralateral non-fractured proximal femur in the same operative session as the surgical repair of the fractured hip. A fragility fracture is defined as a fracture resulting from a fall from standing height.

All subjects will undergo hip fracture repair as recommended by the treating orthopedic surgeon. Repair may include nailing, plates, screws and hip prosthesis.

Subjects may continue to receive, or when appropriate, can be commenced on a treatment regime for osteoporosis. This decision will be made by the treating physician who will determine the best course of action for each patient. The outcome of this decision will have not affect the patient's eligibility for this trial.

Follow-up visits will be conducted at three (3) months, six (6) months, twelve (12) months, and twenty-four (24) months after the procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Fractures Osteoporosis, Postmenopausal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AGN1 Treatment

Subjects who have suffered a fragility hip fracture in one hip, sign the consent form and meet the inclusion and none of the exclusion of the study will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) in the non-fractured hip.

Group Type OTHER

AGN1 Femoral Local Osteo-Enhancement Procedure Kit

Intervention Type DEVICE

A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AGN1 Femoral Local Osteo-Enhancement Procedure Kit

A procedure that is intended to replace lost bone and increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AGN1 Femoral LOEP™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a postmenopausal female
2. Subject has a low-energy fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
3. Subject is ≥ 65 years of age.
4. Subject has willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full duration of the study.
5. Subject is capable of giving written informed consent to participate in the study.

Exclusion Criteria

1. Subject has a prior diagnosis of secondary osteoporosis.
2. Subject has history of any hip surgery or previous hip fracture in the non-fractured hip.
3. Subject has progressive increase in undiagnosed hip pain over the previous six (6) months that in the opinion of the Investigator may suggest other underlying bone or joint pathology (e.g. osteoarthritis, fracture, etc.).
4. Subject has serum calcium levels outside the normal lab range as per local guidelines and reference ranges.
5. Subject has moderate to severe renal insufficiency as per local guidelines and reference ranges.
6. Subject has insulin-dependent diabetes mellitus (IDDM).
7. Subject has Body Mass Index (BMI) \> 30.
8. Subject exhibits excessive smokeless tobacco use or excessive smoking as determined by the principal investigator\*.
9. Subject exhibits excessive alcohol consumption as determined by the principal investigator\*.
10. Subject has radiological evidence of gross bony or joint pathology of the non-fractured hip.
11. Subject treated with corticosteroids or systemic glucocorticoids for ten (10) days in the previous six (6) months.
12. Subject has history of oral or parenteral use of immune-suppressive drugs in the previous twelve months.
13. Subject has history of metabolic bone disease other than osteoporosis (eg. Paget's disease).
14. Subject has a history of auto-immune arthritic diseases including rheumatoid, psoriatic, or those associated with systemic lupus erythematosus, spondyloarthropathy, Reiter's Syndrome or Crohn's Disease.
15. Subject has a history of radiation therapy to the hip or pelvic region.
16. Subject has history of chemotherapy treatment for any condition within the previous five years.
17. Subject has history of any diagnosis and treatment of malignancies (excluding basal cell carcinoma) within the previous five years.
18. Subject has known allergies to implanted device.
19. Subject has severe comorbidity or poor general physical/mental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate.
20. Subject is currently enrolled in another clinical study.

Minimum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No